News
EPHMRA Webinar : Healthcare Market Research in Japan
What should you know when conducting healthcare market research in Japan?
Join EPHMRA for an in-depth look at navigating the Japanese healthcare market, exploring the research landscape and the considerations involved in working across this unique market.
Just 4 weeks to go...
Join us on 21 September for our Basel Chapter Meeting and places still available.
Register Today: https://www.ephmra.org/civicrm/event/register?reset=1&id=33
See our great list of speakers –
EPHMRA AI Community - Launch
September 7 2023, 13:30-14:30 UK time
Artificial Intelligence (AI) – it’s a topic rapidly evolving in our industry. EPHMRA is forming a new AI community to come together, to discuss the AI topics EPHMRA should address and the way forward.
As we welcome the 2023 - 2025 Agency Board members
let's say a BIG thank you to Richard Head and Carolyn Chamberlain who will both leave the Board this year.
Announcing the 2023 – 2025 Agency Board Members
Thanks to everyone who voted – Congratulations to our Winners and welcome to the Board!
Elizabeth Kehler, Managing Director, Adelphi Research
EPHMRA Webinar and Panel Discussion - The Moment of Truth: #Adhesion
September 14 2023 - 13.30 – 14.45 UK time
Speakers:
Adriano Guidi, Menarini Group
EPHMRA is looking forward to welcoming you all to Basel on 21 September 2023 for our annual chapter meeting.
Here is a rundown of what you can expect from the event - https://vimeo.com/849438588?share=copy
A big thank you to our Convenors, without you the 2023 Basel Chapter Meeting wouldn’t be possible.
So an individual thankyou to;
Angela Duffy, Senior Director, Research Partnership
Send in your Synopsis for the 2024 Conference 25 - 27 June, London
The Call for Papers is Launched!
Submission deadline is 21 September 2023
The 2023 Conference was a great success and we are now excited to plan our June 2024 event. Can you add your voice by submitting an idea for a paper?
Our next paper at the 2023 Basel Chapter meeting is…
‘ChatGPT in the spotlight: A critical assessment of its value in rare disease research’